Article

The New York Times on 2020-10-14 02:17

Eli Lilly’s Antibody Trial Is Paused Over Potential Safety Concern

The drugmaker’s experimental antibody treatment is similar to the one President Trump received from Regeneron.

Veterans Affairs

Related news

Eli Lilly Covid-19 Antibody Treatment Trial Is Paused Due To 'Potential Safety Concern'Forbes
Eli Lilly's antibody trial is paused over potential safety concerns Star Tribune
Veterans Affairs , Hennepin County Medical Center
Eli Lilly coronavirus antibody trial paused for potential safety concern The Jerusalem Post (JPost.com)
Eli Lilly antibody trial paused over safety concerns POLITICO
FDA gives emergency clearance to Eli Lilly’s experimental COVID-19 antibody treatment New York Post
BVir Will Test Its Covid-19 Antibody With Eli Lilly’s, Sending Shares Up Again barrons.com
Vír
FDA Authorizes Eli Lilly’s Covid Antibody Therapy For Emergency Use In Young Children Forbes
Eli Lilly halts COVID-19 antibody-treatment trial over ‘safety concern’New York Post
FDA Approves Eli Lilly’s Alzheimer’s Drug Donanemab Forbes
Eli Lilly’s Profit Dented by Higher Costs wsj.com
Lilly’s Covid-19 Antibody Treatment Authorized for Use in Children wsj.com
Eli Lilly’s New Compliance Chief on His Priorities6 min read wsj.com
Canada
US OKs new use for Eli Lilly’s COVID-19 treatment bangordailynews.com
Indianapolis
MEli Lilly’s therapy with solanezumab didn’t decelerate the illness mvtelegraph.com
Brigham City
Eli Lilly’s EFFIENT combination use patent found obvious jdsupra.com
California , United States , Switzerland
Eli Lilly’s sees strength in 2017, shares take off seattletimes.com
FHigh stakes: Eli Lilly’s hunt for an Alzheimer’s drug ft.com
South East Asia , China
BEli Lilly’s Earnings Raise Hopes for Pharmaceutical Stocks barrons.com
FEli Lilly & Co: US regulator delays decision on Eli Lilly’s Alzheimer’s drug ft.com